Petya Milushewa

Dr. Petya Milushewa

Organisation and economics of pharmacy, Medical University of Sofia, Sofia, Sofia-Grad, Bulgaria
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2020 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
BGBrian Godman
Brian Godman
HMHolly McCabe
Holly McCabe
TLTrudy Leong
Trudy Leong
DMDebjani Mueller
Debjani Mueller
AMAntony P. Martin
Antony P. Martin
Johanna Catharina MeyerJohanna Catharina Meyer
Johanna Catharina Meyer
Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed.

3 March 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
TKTzvetan Krustev
Tzvetan Krustev
Petya MilushewaPetya Milushewa
Petya Milushewa
KTKonstantin Tachkov
Konstantin Tachkov
Objective: Polypharmacy and inappropriate prescribing are overlooked issues in Bulgaria. We aimed at collecting and analyzing global literature on the most prevalent risk factors and investigating what they could reveal about current practice. Materials and Methods: A systematic narrative review and meta-analysis was conducted on the topic, investigating the prevalence of polypharmacy, odds of potentially inappropriate medications (PIMs) due to polypharmacy, and the likelihood of developing a drug-related problem (DRP) due to PIMs. The results were then related to current demographic statistics to estimate the potential impact on Bulgarian elderly patients. Results: The prevalence of polypharmacy was estimated at 41% in elderly populations. The odds of a potentially inappropriate medication being prescribed were 2.095, with an expected 30.84% of those leading to a DRP. These numbers indicated that the expected Bulgarian elderly with polypharmacy should be 709,676 with 212,903 cases of DRPs. Conclusion: Global polypharmacy rates seem to be on the rise, with an expected increase in DRPs.

22 December 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
TKTzvetan Krustev
Tzvetan Krustev
Petya MilushewaPetya Milushewa
Petya Milushewa
KTKonstantin Tachkov
Konstantin Tachkov
KMKonstantin Mitov
Konstantin Mitov
GPGuenka Petrova
Guenka Petrova
Objective: This study aims to evaluate the use of STOPP/START criteria in the identification of Potentially inappropriate medication and potential prescribing omissions in older patients with cardiovascular diseases in Bulgaria. Excessive morbidity and mortality has been linked to drug-related problems and increased use of healthcare services and is an understudied problem for Bulgaria.Materials and methods: A prospective, questionnaire-based study was conducted among 543 older patients across 25 pharmacies in Bulgaria. Socio-demographic characteristic, disease profile, symptoms, and medication data were collected. The questionnaire was developed for the purposes of the EUROAGEISM project. Out of all 543 patients, only those with documented cardio-vascular diseases were extracted and the medication profile per patient was evaluated for Potentially inappropriate medication (PIMs) and potentially prescribing omissions (PPOs) using STOPP/START criteria version 2. In addition, several risks for potentially inappropriate prescribing (PIPs), PPOs and PIMs were calculated with the focus being on the Odds and Risks to develop a PIP.Results: Four hundred and twenty eight from 531 patients with known therapy for cardiovascular diseases (CVDs) were included in the analysis of PIP (40.52% aged 65–69 years, 61.88% female, 64% had up to 6 comorbidities, and 21.72% presenting with polypharmacy). A total of 71 PIMs in 64 patients with polypharmacy were identified during applying STOPP criteria. 56% of patients taking above five medicines daily had PIMs. The majority of PIMs (31%) were related to CVDs treatment, followed by PIMs in the treatment of endocrine diseases (22.54%), duplication of medicines (8.46%) and prolonged treatment with benzodiazepines (8.46%). Forty four PPOs were identified with START criteria. 22.72% were related to lack of proton pump inhibitors (PPI) in the presence of gastroesophageal disorders, and the same percentage was for lack of Calcium-vitamin D supplementation in osteoporosis. Applying the methodology of risks calculation the sample risk for PPO was 2.1% and for PIM 3.4%. At sample level the relative risk for PPO was 62% out of the risk for PIM and at population level varied between 42.8 and 89.8% and it is statistically significant. The number needed to treat for the event to happen is 77.5, meaning that at every 78 prescriptions there is a chance to appear PIP.Conclusion: Application of methodologies for detection of potentially inappropriate prescribing is not part of routine clinical practice in Bulgaria. Our study demonstrates a high percentage of potentially inappropriate medication among older patients with polypharmacy. Along with the aging population in Bulgaria, economic burden of polypharmacy and the prevalence of cardiovascular diseases, it is especially important to address potentially inappropriate medication use in cardiovascular patients. There is a considerable necessity for implementation of measures for early detection of potentially inappropriate medication and potentially prescribing omission as a part of de-prescribing strategies in older patients.

5 February 2024 in Bioanalysis
Verified
Journal Article
Closed access
PTPhilip Timmerman
Philip Timmerman
MBMatthew Barfield
Matthew Barfield
EPEnric Bertran Portabella
Enric Bertran Portabella
SCSalvatore Calogero
Salvatore Calogero
KCKyra Cowan
Kyra Cowan
KZKatja Zeiser
Katja Zeiser
The ICH M10 guideline on bioanalytical method validation and sample analysis is being adopted since 2023. However, and inevitably, some paragraphs or requirements remain ambiguous and are open for ...

1 January 2021 in Biotechnology & Biotechnological Equipment
Verified
Journal Article
Open access
MDMaria Dimitrova
Maria Dimitrova
Petya MilushewaPetya Milushewa
Petya Milushewa
EPElina Petrova
Elina Petrova
DMDesislava Mihaylova
Desislava Mihaylova
NTNezabravka Tzvetanova
Nezabravka Tzvetanova
GPGuenka Petrova
Guenka Petrova
Breast cancer is the most common oncologic disease among women worldwide. Survival rates vary significantly and depend on early diagnosis practice and access to treatment. Triple negative breast cancer (TNBC) accounts for 12–15% of all breast cancers. We performed a one-year real-life retrospective study on the patho-histological status and treatment of a representative cohort of patients with TNBC in Bulgaria. We collected anonymised data for TNBC patients from the electronic artificial intelligence platform Sqilline - Danny Platform. Demographic characteristics, data on biomarkers, TNM (Tumor, Nodule, Metastasis) stage, therapeutic regime, line and changes in treatment were chronologically analysed for all patients. The results were processed through descriptive statistics. For the observed period, Jan 2019–Dec 2019, 6880 breast cancer patients from eight major oncology hospitals were included in the database. The average age of the women was 60 y; 234 (3.4%) of them were diagnosed with TNBC; 10% had unknown TNM stage. The majority of the patients were assigned to chemotherapy (84%) of which 35% were on adjuvant. Most changes in the therapy were observed in the neo-adjuvant group).The results from this study provide evidence that the treatment patterns of TNBC, and changes in therapy are in compliance with international guidelines. We identified less patients with TNBC than the frequencies reported in international epidemiological studies. This might be attributed to lack of funding of necessary tests or insufficient data in patients record. The study confirms that dynamic patient registers are important for performing a real-world studies of treatment patterns.

1 January 2020 in Sage Open Medicine
Verified
Journal Article
Open access
PDF file
Petya MilushewaPetya Milushewa
Petya Milushewa
MDMiglena Doneva
Miglena Doneva
Guenka PetrovaGuenka Petrova
Guenka Petrova
Objectives: This study aims to analyze the reimbursement and cost of biological therapy for severe asthma in Bulgaria during 2014–2019 from the perspective of the National Health Insurance Fund. Methods: It is a retrospective, Marco-costing, top-down study of the expenditures for biological products for severe asthma. The changes in the cost paid by the National Health Insurance Fund per year, per product, and per patient during 2015–2020 were systematized and calculated. The utilization of biologicals was analyzed by calculating the defined daily dose/1000inh/day. Three databases were searched—the European Medicines Agency for the date of marketing authorization of biological products, National Council of Prices and Reimbursement for the date of their respective inclusion in the positive drug list, and National Health Insurance Fund about the number of patients with asthma, reimbursed sum for all asthma patients, and number of packages sold of biological products. Results: At the end of 2019, five international non-proprietary names of biologicals with indication for severe asthma had received European marketing authorization, and three of them were included in the Bulgarian positive drug list—omalizumab, mepolizumab, and benralizumab with a 75% reimbursement. Upon their introduction into the positive drug list, the reimbursed expenditures for asthma therapy started to increase from 27 million in 2014 to 33 million BGN in 2019 (€13.5–€16.5 million). The cost of therapy with biologicals rose from 16% to 24% of all anti-asthmatic medicines budget. The National Health Insurance Fund database reported that between 47,000 and 52,000 of patients with asthma, 466 are on biological therapy. The yearly cost of one asthma patient ranges between 512 and 615 BGN (€258–€307), and the yearly per-patient cost of severe asthma is 16,666 BGN (appr. €8333). Total utilization in defined daily dose/1000inh/day increases from 0.0199 to 0.0383 from 2015 to 2019. Conclusion: The access to biological therapy through the reimbursement system has improved during the last 3 years. The cost of therapy is posing a high burden on the National Health Insurance Fund and on the patients and is expected to increase due to the small number of patients on biological therapy currently in comparison to all reimbursed asthmatics.